MiLaboratories
Maker of Platforma, a computational biology platform for analysing sequencing data in biologics discovery.
Private company- Sector
- Biotech
- Based in
- San Francisco, United States
- Invested
- Aug 2024
MiLaboratories makes software for computational biology. Its main product, Platforma, turns sequencing data into analysis that supports decisions in biologics discovery. It offers ready-made workflows for antibody discovery, immune research, translational research and multiomics. Platforma can be deployed on a desktop, a server, HPC clusters or a private cloud, and an SDK lets teams build their own analysis blocks.
The company's roots are in MiXCR, an open-source tool for analysing T-cell and B-cell receptor sequencing that its founding scientists created in 2013. MiXCR became widely used for immune repertoire profiling. MiLaboratories launched Platforma in March 2024, and academic and non-profit researchers can use it free.
MiLaboratories is headquartered in San Francisco and runs an R&D office in Bilbao, Spain. In October 2024 it announced a Series A led by Madrid-based Kfund.
As of 29 Sep 2026
Why I own it
Biology is becoming a data problem. MiLaboratories builds software that analyses sequencing data for antibody discovery and immune research, and its MiXCR tool is widely used by researchers.
As AI speeds up drug discovery, labs need rigorous, reproducible analysis underneath it. That kind of dependable software becomes more valuable as AI spreads, not less.
Then · Aug 2024
Since I invested
- Held for
- 2 years, 2 months
- Status
- Active
